Lactoferrin reduces the duration and severity of infection in neutropenic patients receiving chemotherapy for acute myleogenous leukemia. - GreenMedInfo Summary

Abstract Title:

Antibacterial prophylaxis with lactoferrin in neutropenic patients.

Abstract Source:

Eur J Clin Microbiol Infect Dis. 1989 Apr;8(4):310-3. PMID: 2497005

Abstract Author(s):

U Trümpler, P W Straub, A Rosenmund

Abstract:

The prevention of enterogenic infection by human lactoferrin was tested in five neutropenic patients receiving chemotherapy for acute myelogenous leukemia. Lactoferrin did not significantly delay the onset of infection but reduced its duration and severity as judged from the course of fever. Compared with nine matched controls, lactoferrin-treated patients had a lower incidence of bacteremia on the whole and of gram-negative bacteremia in particular.

Article Published Date : Apr 01, 1989

Study Type : Human Study

Additional Links

Substances : Lactoferrin : CK(500) : AC(195)

Diseases : Leukemia: Acute myelogenous leukemia (AML) : CK(162) : AC(67), Neutropenia : CK(90) : AC(22), Neutropenia: Chemotherapy Induced : CK(73) : AC(17), Neutropenia: Cyclic : CK(48) : AC(16)

Print Options

Some features are currently member only features. If you are already a member, please login. Otherwise, click here to become a member.

Printer-friendly version

Lactoferrin reduces the duration and severity of infection in neutropenic patients receiving chemotherapy for acute myleogenous leukemia. - GreenMedInfo Summary

Print Options

Key Research Topics

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.